
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis
O’Day, Ken, Meyer, Kellie, Miller, Ross M., Agarwal, Sonalee, Franklin, MegVolume:
14
Langue:
english
Journal:
Journal of Medical Economics
DOI:
10.3111/13696998.2011.602444
Date:
October, 2011
Fichier:
PDF, 373 KB
english, 2011